Protalix biotherapeutics, inc. (PLX)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
REVENUES

-

-

-

-

-

-

-

-

-

-

-

-

-

4,670

1,769

679

0

1,336

1,336

1,692

-

-

2,425

6,696

-8,116

2,284

2,264

3,568

1,172

3,724

26,113

3,861

2,362

1,132

764

4,128

3,184

1,141

REVENUES

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,396

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

COMPANY'S SHARE IN COLLABORATION AGREEMENT

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,311

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

COMPANY'S SHARE IN COLLABORATION AGREEMENT

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

261

687

-

1,075

800

400

-1,124

1,666

-855

-133

-1,673

-235

-5,382

1,872

-1,065

-528

COST OF GOODS SOLD

2,950

3,205

2,695

2,045

2,278

1,917

2,183

2,924

1,554

6,066

5,523

2,088

1,952

4,248

1,675

523

0

223

225

282

-6,846

1,798

1,605

4,073

-3,876

1,587

1,318

971

1,178

2,367

3,279

1,320

395

220

132

778

-

0

GROSS PROFIT (LOSS)

-

-

-

-

-

-

-

-

-

-

-

-

-

422

94

156

0

1,113

1,111

1,410

-3,407

1,909

1,081

3,310

-6,515

1,772

1,746

2,997

-1,130

3,023

21,979

2,408

294

677

-4,750

5,222

2,119

613

RESEARCH AND DEVELOPMENT EXPENSES

9,669

10,000

13,323

11,701

10,701

10,071

7,476

7,286

9,781

7,118

9,304

5,967

6,712

6,353

10,013

7,334

7,698

5,068

6,023

6,100

4,072

8,052

7,076

8,152

5,758

7,723

7,990

7,754

8,948

8,326

10,544

8,847

9,147

9,340

8,768

10,563

6,322

10,347

Less - grants

-

-

0

3

-

-

235

843

791

729

478

1,338

1,004

1,297

2,194

1,309

1,291

1,116

1,329

1,128

-1,018

1,947

2,114

2,085

-2,836

2,086

1,532

2,431

2,321

1,963

1,689

2,003

-

1,422

1,449

-

-

-

less - grants and reimbursements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,292

2,776

849

RESEARCH AND DEVELOPMENT EXPENSES, NET

-

-

13,323

11,698

-

-

7,241

6,443

8,990

6,389

8,826

4,629

5,708

5,056

7,819

6,025

6,407

3,952

4,694

4,972

5,090

6,105

4,962

6,067

8,594

5,637

6,458

5,323

6,627

6,363

8,855

6,844

7,535

7,918

7,319

8,271

3,546

9,498

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

3,014

2,587

2,068

2,230

2,172

4,088

2,158

2,498

3,343

2,836

2,814

2,537

3,141

2,014

2,206

1,995

1,293

2,163

2,001

1,822

1,939

2,012

1,566

3,711

1,986

1,780

2,182

2,103

-

-

-

-

-

-

-

-

-

-

GENERAL AND ADMINISTRATIVE EXPENSES

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,220

3,504

1,629

1,617

1,526

1,799

1,989

1,421

1,265

OPERATING LOSS

2,200

-1,544

-5,839

-5,534

-3,672

-3,741

-6,744

-5,151

-9,582

-7,765

-10,805

-6,365

-8,720

-6,648

-9,931

-7,864

-7,700

-5,002

-5,584

-5,384

-10,436

-6,208

-5,447

-6,468

-17,095

-5,645

-6,894

-4,429

-10,167

-5,560

9,620

-6,065

-8,858

-8,767

-13,868

-5,038

-2,848

-10,150

FINANCIAL EXPENSES

2,089

2,050

1,907

1,920

1,861

1,811

1,793

2,220

913

3,680

3,045

2,087

1,477

910

901

904

906

1,030

642

1,157

1,295

1,851

874

915

911

131

9

14

-

-

-

-

-

-

-

-

-

-

FINANCIAL INCOME

180

34

3

190

99

230

75

132

-1,485

8

40

1,625

-17

268

96

242

35

17

43

28

-93

49

202

38

174

29

66

122

-

-

-

-

-

-

-

-

-

-

LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE

-

-

-

-

-

-

-

-

0

0

14,260

-52,321

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

FINANCIAL EXPENSES - NET

-1,909

-2,016

-1,904

-1,730

-1,762

-1,581

-1,718

-2,088

-3,723

-3,672

11,255

-52,783

6,096

-642

-805

-662

-871

-1,013

-599

-1,129

-1,388

-1,802

-672

-877

-737

-102

57

108

-

81

22

-

-

-

-

-

-

-

LOSS FROM CONTINUING OPERATIONS

-

-

-

-

-

-

-

-

-

-

-

-

-2,624

-7,290

-10,736

-8,526

-8,571

-6,015

-6,183

-6,513

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

LOSS FROM DISCONTINUED OPERATIONS

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-117

-72

81,471

2,195

1,112

541

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

FINANCIAL INCOME - NET

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

161

-

-108

179

-14

374

109

NET LOSS FOR THE YEAR

291

-3,560

-7,743

-7,264

-5,434

-5,322

-8,462

-7,239

-13,305

-11,437

450

-59,148

-2,624

-7,290

-10,853

-8,598

72,900

-3,820

-5,071

-5,972

-8,469

-8,010

-6,119

-7,345

-10,885

-5,747

-6,837

-4,321

-9,877

-5,479

9,642

-5,904

-8,913

-8,875

-13,689

-5,052

-2,474

-10,041

NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED

-1.11

-0.02

-0.05

-0.05

-1.65

-0.04

-0.06

-0.05

-

-0.09

-

-0.48

-

-0.07

-

-0.09

0.76

-0.04

-0.05

-0.06

-0.24

-0.09

-0.07

0.08

-0.22

-0.06

-0.07

0.05

-

0.06

-

0.07

-

-0.10

-

0.06

0.03

0.12

(Loss) earnings from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.07

-

-0.09

-0.10

-0.06

-0.06

-0.07

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

0.86

0.02

0.01

0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) earnings per share of common stock

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.11

-

-

-

-0.16

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share of common stock

-

-

-

-

-

-

-

-

-

-

-0.06

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

-

-0.16

-

-

-

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED

-148,619,710

148,382

148,382

148,382,299

-145,541,959

148,187

146,644

145,305,982

-

132,549

-

124,467

-

99,821

-

99,715

98,909

93,943

93,635

93,200

93,088

92,971

92,820

92,686

92,557

92,433

92,297

92,184

-

91,929

-

87,821

-

85,585

-

-

-

-

BASIC

-

-

-

-

-

-

-

-

-

-

127,523

-

-

-

99,758

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

91,526

-

-

-

85,579

-

-

-

DILUTED

-

-

-

-

-

-

-

-

-

-

192,598

-

-

-

99,758

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

94,881

-

-

-

85,579

-

-

-

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE of common stock, basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

81,744

80,914

80,872

Goods [Member]
REVENUES

3,780

5,126

3,430

3,530

1,756

663

2,006

4,553

2,469

7,526

6,358

2,889

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License and R&D Services [Member]
REVENUES

13,979

9,122

8,817

6,909

8,597

11,672

2,832

2,161

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-